Risk factor
Meaningful price volatility
Profitability factor
Overvalued vs peers
About
Morepen Laboratories Limited is an Indian pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), proprietary and generic pharmaceutical formulations, and a diverse range of home healthcare products. Its API portfolio encompasses compounds utilized in the creation of drugs for conditions such as allergies, asthma, elevated cholesterol, hypertension, and diabetes. The company also supplies an array of point-of-care and medical devices for home use, including diagnostic tools like air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse oximeters, nebulizers, glucometers with accompanying strips, as well as hygiene products such as sanitizers, disinfectant solutions, masks, and gloves. Among its well-known branded products are Burnol, a cream for treating burns; Lemolate, an offering for cough and cold relief; and Fiber-X, a psyllium husk supplement. Furthermore, Morepen produces finished drug formulations covering various therapeutic areas, including gastrointestinal health, antibiotics, vitamins, nutritional support, anti-diabetics, and cardiovascular conditions. Beyond these offerings, the company undertakes contract manufacturing for other businesses and participates in brand sharing agreements. Its comprehensive range of over-the-counter (OTC) products is marketed under the recognizable Dr. Morepen brand. The company's global footprint extends to approximately 75 nations, where its products are exported. Established in 1984, Morepen Laboratories Limited maintains its headquarters in New Delhi, India.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.